The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

D. Koutsimpelas\textsuperscript{a} M. Bjelopavlovic\textsuperscript{a} R. Yetis\textsuperscript{a} K. Frauenknecht\textsuperscript{b} B. Adryan\textsuperscript{d}
I. Schmidtmann\textsuperscript{c} H. Gouveris\textsuperscript{a} K. Fruth\textsuperscript{a} U.R. Heinrich\textsuperscript{a} R.H. Stauber\textsuperscript{a}
W.J. Mann\textsuperscript{a} J. Brieger\textsuperscript{a}

\textsuperscript{a}Department of Otorhinolaryngology, Head and Neck Surgery, \textsuperscript{b}Department of Neuropathology and \textsuperscript{c}Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; \textsuperscript{d}Cambridge Systems Biology Centre and Department of Genetics, University of Cambridge, Cambridge, UK

Key Words
Vestibular schwannoma · Vascular endothelial growth factor · Vascular endothelial growth factor receptors · Neuropilin 1 · Proliferative activity · Irradiation

Abstract

Background/Aims: The molecular mechanisms downstream of mutated neurofibromatosis type 2 (NF2) gene resulting in the growth and development of vestibular schwannoma (VS) are controversial. Several lines of evidence suggest the involvement of the vascular endothelial growth factor (VEGF) pathway in VS development. Given that recent studies of VEGF blockade in patients with NF2-associated VS showed positive effects on VS growth control, we initiated this comprehensive study of the VEGF pathway in sporadic VS. Methods: A tissue microarray analysis of 182 sporadic VS was conducted. The expression of VEGF and its receptors as well as the proliferative activity of the tumors were quantified. The expression data were correlated to tumor volumes and diameters as well as to tumor recurrence and previous irradiation. Results: All studied tumors expressed VEGF and its receptors. Proliferative activity was related to the growth characteristics of the tumors. Moreover, we found significantly higher VEGF levels in recurrent tumors ($p = 0.0387$) and in preoperatively irradiated tumors ($p = 0.0213$). Conclusion: Our data suggest a relevant role of the VEGF pathway in VS growth and therapy outcome. Therefore, targeting this pathway using antiangiogenic compounds might be beneficial for patients with sporadic VS, especially those with recurrent or irradiated tumors.
Vascularization and new blood vessel development are an important aspect of solid tumor growth in general [3] and have also been involved in the specific case of VS growth [4–7]. Among the numerous proangiogenic growth factors, the vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis. VEGF functions are largely mediated through three receptors, the VEGF receptor 1 (VEGFR-1/Flt), VEGF receptor 2 (VEGFR-2/Flk), and Neuropilin 1 (NP1) [8, 9]. VEGFR-1/Flt and VEGFR-2/Flk are expressed by Schwann cells, and VEGF has been found to act as a survival factor in these cells [10]. NP1 is a 120- to 130-kDa single-spanning transmembrane glycoprotein, initially characterized as a neuronal receptor for semaphorin, and more recently recognized as a VEGF coreceptor [9, 11].

Besides its proangiogenic properties, VEGF also has cytoprotective activities [8, 12–14]. Tumor cell resistance to apoptosis induction due to cellular distress induced by irradiation or chemotherapy is increased after VEGF stimulation [15, 16].

Given the promising results of the clinical application of anti-VEGF active compounds in patients with NF2-associated VS [5, 17], a comprehensive analysis of the VEGF pathway in sporadic VS was warranted to provide a molecular basis for an antiangiogenic treatment decision.

In the present report we present our comprehensive analysis of VEGF, VEGFR-1, VEGFR-2, and NP1 expression in the tumor specimens of 182 sporadic VS patients.

Materials and Methods

Patients/Specimens

A total of 182 consecutive adult patients with solitary, sporadic, unilateral VS operated on at the Department of Otorhinolaryngology, University Medical Center of the Johannes Gutenberg University Mainz, Germany, during the years 2000–2007 were included in this study. The median age was 52 years (range 18–78); 79 patients were male and 103 female. Thirteen patients had already been treated prior to operation with stereotactic radiosurgery to avoid unspecific binding, primary antibodies (VEGF sc-152, 1:200; VEGFR-1/Flt-1 sc-316, 1:150; VEGFR-2/Flk-1 sc-6251, 1:100; NP1 sc-5307, 1:75; Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA; Ki-67 M7240, 1:200; DAKO A/S, Glostrup, Denmark) were overlaid overnight at 4 °C. Slides were then incubated with goat anti-mouse or goat anti-rabbit biotinylated secondary antibody (E0433, 1:250; E0432, 1:250; DAKO A/S) and streptavidin/HRP (P0397, 1:100; DAKO A/S). All washing procedures were performed in PBS. Slides were counterstained with hematoxylin. Negative controls were performed, substituting the primary antibody with PBS. Normal kidney tissue served as positive control.

Immunohistochemistry

Immunohistochemical analysis was performed using standard procedures. In brief, dewaxing and rehydration followed by blocking of endogenous peroxidase with 3% H2O2/methanol was carried out. After preincubation with 10% normal serum in 2% bovine serum albumin/phosphate-buffered saline (PBS) for 20 min to avoid unspecific binding, primary antibodies (VEGF sc-152, 1:200; VEGFR-1/Flt-1 sc-316, 1:150; VEGFR-2/Flk-1 sc-6251, 1:100; NP1 sc-5307, 1:75; Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA; Ki-67 M7240, 1:200; DAKO A/S, Glostrup, Denmark) were overlaid overnight at 4 °C. Slides were then incubated with goat anti-mouse or goat anti-rabbit biotinylated secondary antibody (E0433, 1:250; E0432, 1:250; DAKO A/S) and streptavidin/HRP (P0397, 1:100; DAKO A/S). All washing procedures were performed in PBS. Slides were counterstained with hematoxylin. Negative controls were performed, substituting the primary antibody with PBS. Normal kidney tissue served as positive control.

Quantification of the Expression

For evaluation of the VEGF, VEGFR-1, VEGFR-2, and NP1 expression the stained area and intensity of each section in five fields were measured by a computer-based image analysis method, as described in detail previously [18, 19]. In brief, three representative areas (400× magnification, corresponding to 25 × 25 μm) of each tissue sample were documented in .jpg using an inverted microscope (Zeiss, Jena, Germany). For quantification, the .jpg documents were analyzed using Photoshop (Adobe Systems Inc., San Jose, Calif., USA). The stainings were quantified by the multiplication of the stained area by the staining intensity and expressed as arbitrary units (AU). This method allows relative comparison of expression levels. Computer-based image analysis was performed by the same researcher (M.B.) for minimum variability and later confirmed by a second scientist (U.R.H.) in a blinded fashion.

Proliferative Activity

Using a light microscope we evaluated five areas of the stained sections at 400-fold magnification. At least 500 cells were evaluated per section and the mean percentage of the Ki-67 positive tumor cells was calculated.
Statistics

The Wilcoxon rank sum test was used to assess whether differences between two groups were significant. Pearson’s product moment correlation was used for statistical data evaluation, with $p < 0.05$ as the level of significance. Data shown are mean values ± SD. All calculations were performed using the SPSS 15.0 (SPSS, Inc., Chicago, Ill., USA). Data were not adjusted for multiple testing because of the explorative nature of the study.

Hierarchical clustering of the tumors was performed based on their expression of VEGF, VEGFR-1, VEGFR-2, NP1, proliferative index, tumor volume and diameter. The values for each parameter were normalized and the deviation from the mean was color coded (blue > mean, yellow < mean). We used k-means clustering with 3 groups in Genesis v1.75 to derive three biologically distinct groups [20]. The selection of three groups was motivated by a previous hierarchical clustering approach that allowed us to identify the largest grouping visually.

Results

In total, 182 patients (age 52 ± 10.6 years; range 18–78) were studied. Tumor volume varied between 24 and 37,679 mm$^3$ (mean 2,404 ± 2,329) while the maximum tumor diameter ranged between 3.2 and 41 mm (mean 15.73 ± 8.82). The proliferation index ranged between 0.1 and 2.5% (mean 0.91 ± 0.54). Representative immunohistochemical stainings are shown in figure 1.

By using the VEGF antibody, cytoplasmic staining of the tumor and endothelial cells was observed (fig. 1). VEGF expression varied from 1.26 to 5,025 AU (mean 570 ± 497). The VEGF-receptors were expressed on the cell membrane as expected (fig. 1). Expression of VEGFR-1/Flt varied between a minimum of 14 AU and a maximum of 3,483 AU (mean 875 ± 604), VEGFR-2/Flk between 23 and 1,723 AU (mean 573 ± 379), and NP1 between a minimum of 61 AU and a maximum of 1,924 AU (mean 494 ± 252).

We found a significant positive correlation of VEGFR-2 expression to both VEGFR-1 and NP1 expression, and a significant positive correlation of the proliferation index to the tumor volume and tumor diameter (fig. 2a–e). Nonetheless, no correlation between VEGF expression and VEGFR-1, VEGFR-2 or NP1 expression was observed (data not shown). The age of the patients did not correlate with the results of the immunohistochemical quantification or with the tumor growth characteristics. Expression of neither VEGF nor its receptors correlated with the proliferation indexes or the growth characteristics of the tumors.

Interestingly, significantly increased VEGF levels were found in the groups of recurrent (p = 0.0387) and preoperatively irradiated tumors (p = 0.0213) when compared to the VEGF levels of the group of primary VS patients (fig. 3, 4). Comparison of these three groups concerning the proliferation indexes, VEGF receptor expression, growth characteristics, and the age of the patients revealed no differences (data not shown).

Finally, we performed hierarchical clustering of the tumors based on their expression of VEGF, VEGFR-1, VEGFR-2, NP1, proliferative index, tumor volume and maximum diameter (fig. 5). The tumors clustered in three distinct groups. The first group comprised of tumors with high proliferative activities and high VEGF, VEGFR-1, VEGFR-2 and NP1 expression combined with large volumes and large diameters (n = 35; fig. 5a). The second group of tumors showed high proliferative activities and high VEGF, VEGFR-1, VEGFR-2 and NP1 expression but low volumes and small diameters (n = 42; fig. 5b). The third group comprised of tumors with low proliferative activities and low expression of VEGF and all three receptors as well as low volumes and small diameters (n = 105; fig. 5c). Interestingly, the higher percentage of tumors treated with radiation therapy prior to operation was found in the second group of tumors (5/42, 12%; fig. 5d), while the higher percentage of recurrent tumors clustered in the first group of tumors (8/35, 23%; fig. 5e).

Discussion

Despite the initiation of clinical trials evaluating antiangiogenic active compounds for the therapy of familial VS, no large comprehensive analysis of the VEGF pathway in sporadic VS patients has been available until now. We here show that sporadic VS tumor growth is associated with proliferative activity and that tumor VEGF levels are correlated to tumor recurrence and radiation therapy failure.

Angiogenesis is a major prerequisite for the proliferation and progression of several neoplasms [3]. Despite the fact that VS are generally slow-growing tumors, and therefore may not need excessive vascularization for progression, a functional vascular system still remains important for further growth. VEGF is one of the most potent angiogenic factors [3, 8] and is expressed in most tumor entities [21]. Pietsch et al. [22] and Nishikawa et al. [23] analyzed several types of brain tumors for VEGF expression and demonstrated this cytokine not only in strongly vascularized brain tumors such as glioblastomas but also in the less vascularized astrocytomas and me-
VEGF and Its Receptors in Vestibular Schwannomas

Moreover, VEGF has been reported to act as a survival factor for Schwann cells [10]. Accordingly, upregulated VEGF expression has been previously demonstrated in VS [5, 7, 24–26]. In our present study also, all samples expressed VEGF. Moreover, we found that all of the tumors expressed VEGFR-1/Flt and VEGFR-2/Flk as well as the coreceptor NP1. Expression of VEGF and of all three receptors was identified both on tumor cells and on endothelial cells of tumor-associated vessels, which is in line with previous reports [5, 7, 26, 27].

**Fig. 1.** Representative immunohistochemical stainings of tumor samples showing weak and intense staining for VEGFR-1, VEGFR-2, Ki-67, NP1 and VEGF. Scale bar = 100 μm.
may suggest a cross-talk between tumor cells and vessels in a paracrine-stimulating manner.

The available data concerning the proliferative activity of VS are contradictory. In a previous study, large VS exhibited enhanced proliferative activity compared with smaller lesions [28]. Similar results have also been reported by other authors describing a higher proliferative activity in large tumors [29–31]. However, these results have been contradicted by Charabi et al. [32, 33], who found no correlation between tumor size and prolifera-

Fig. 2. Scatter plots show a positive correlation between VEGFR-1 and VEGFR-2 expression (a), NP1 and VEGFR-1 expression (b), NP1 and VEGFR-2 expression (c), tumor volume and proliferation index (d), and tumor diameter and proliferation index (e).

Fig. 3. VEGF expression comparing recurrent and primary tumors. VEGF expression in samples from the recurrent tumors is significantly higher compared to VEGF expression in samples from primary tumors. Differences were calculated by the Wilcoxon rank sum test; * p < 0.05.

Fig. 4. VEGF expression comparing tumors previously treated with radiation therapy and primary tumors. VEGF expression in samples from tumors irradiated prior to surgery is significantly higher compared to samples from primary tumors. Differences were calculated by the Wilcoxon rank sum test; * p < 0.05.
In our current analysis we found relatively low proliferative indexes, as expected for a benign neoplasm. Furthermore, we were able to identify a correlation of proliferative activity to tumor volume and tumor diameter. One possible explanation for these conflicting literature reports is that the assessment of proliferation indexes can be influenced by the point of time when the operation is performed and the tissue becomes available for analysis, since many VS do not grow continuously but can remain stable over a long period of time [2]. Niemczyk et al. [34] have reported in a study of 12 VS that the group of tumors which had been shown to grow at the time of surgical removal had a higher proliferation index than the group of stable (nongrowing) tumors. A further factor that may influence the value of the assessed Ki-67 index is the exact location of the biopsy taken.

### Fig. 5

Hierarchical clustering of VS based on their expression of VEGF, VEGFR-1/Flt, VEGFR-2/Flk, NP1, proliferative index, volume and maximum diameter. The values for each parameter were normalized and the deviation from the mean was color coded (blue > mean, yellow < mean). Tumors were classified into three distinct clusters.

- **a** Tumors with large diameters, high volumes, and proliferative activities combined with high VEGF, VEGFR-1, VEGFR-2, and NP1 expression (group I, n = 35).
- **b** Tumors with low volumes and small diameters but high expression of VEGF, VEGFR-1, VEGFR-2, NP1, and high proliferative indexes (group II, n = 42).
- **c** Tumors with small diameters, low volumes, and proliferative activities combined with low VEGF, VEGFR-1, VEGFR-2, and NP1 expression (group III, n = 105).
- **d** Distribution of the tumors treated by radiation therapy prior to surgery. Previously irradiated tumors clustered more frequently in group II and were associated with high proliferative indexes and high VEGF and VEGF receptor expression.
- **e** Distribution of the recurrent tumors. Recurrent tumors clustered more frequently in group I and were associated with high proliferative indexes and high VEGF and VEGF receptor expression.
ported in glioblastoma cell lines were necessary. Data of the recurrent tumor in the same patient would be necessary. Expression of the primary tumor and of the respective tissue, a comparison between the data regarding VEGF and its receptors were more frequently observed than tumors with low proliferative activity and low VEGF and VEGF receptor expression. Similar results were observed for the recurrent tumors, suggesting that the VEGF pathway is of relevance for the proliferation of recurrent and irradiated tumors.

Interestingly, the recurrent tumors and the tumors treated with radiosurgery prior to operation showed a considerable elevated VEGF expression in comparison to the primary tumors. In a previous study, Uesaka et al. [27] reported an increased VEGF mRNA expression in recurrent VS, and suggested a possible involvement of VEGF in the growth or recurrence of these tumors. Our data from the present manuscript support these findings. This increased VEGF expression in the recurrent tumors may be the result of surgical trauma or the result of an intrinsic propensity of a subset of VS tumors. Since most of the recurrent VS tumors are tumor persisters, it might be assumed that in patients with tumor persistence after surgical treatment the aforementioned intrinsic propensity might accelerate the clinical/radiological manifestation of recurrence. To further clarify this issue, a comparison between the data regarding VEGF expression of the primary tumor and of the respective data of the recurrent tumor in the same patient would be necessary.

Furthermore, Uesaka et al. [27] reported that two tumors which had undergone radiation therapy before surgery also showed an increased VEGF mRNA expression. The authors hypothesized an upregulation of VEGF mRNA expression by radiation, which has been associated with rapid tumor expansion. Upregulation of VEGF by irradiation has been previously reported in a variety of neoplasms [36–39]. The present data from our large-scale study support the hypothesis that irradiation of VS might lead to an upregulation of VEGF, which in the long term might be associated with progress of a residual tumor. However, a further point has to be addressed concerning the increased VEGF expression in the group of irradiated tumors. It has been previously reported that both endothelial cells of epithelial tumors and tumor cells themselves found under cellular distress might be protected by VEGF [12, 15, 16]. A similar effect of VEGF has been reported in glioblastoma cell lines [13]. In our study we found increased VEGF expression in the group of irradiated tumors. This group included tumors which have shown progress after the radiation treatment and therefore have been surgically removed. It might be possible that these tumors express high levels of VEGF per se. These increased VEGF levels might contribute to the protection of the endothelial and/or tumor cells during the radiation. Therefore, we hypothesize that a VEGF-mediated protection of VS endothelial and/or tumor cells might be a mechanism resulting in different radiation sensitivity. Consequently, the failure of radiation therapy to control VS tumors might depend on high VEGF expression levels. Whether these tumors express increased VEGF per se, or the increased VEGF expression is an epiphenomenon resulting from the radiation, remains unclear. A future in vitro study investigating further the association of radiation therapy with the expression of VEGF in VS will be the obvious extension of the present investigation.

Furthermore, cluster analysis revealed that in the group of VS patients with irradiated tumors, tumors with high proliferative indexes expressing high levels of VEGF and its receptors were more frequently observed than tumors with low proliferative activity and low VEGF and VEGF receptor expression. Similar results were observed for the recurrent tumors, suggesting that the VEGF pathway is of relevance for the proliferation of recurrent and irritated tumors.

These data are of potential clinical relevance given that recent studies of VEGF blockade with bevacizumab in patients with NF2-associated VS showed a reduction in the volume of most VS [5, 17]. This has been attributed primarily to tumor shrinkage due to changes in intratumoral vascular permeability and subsequently due to the reduction of the intratumoral edema as well as to increased tumor cell death through the antivascular effect [5, 6, 17].

Since sporadic VS express VEGF and its receptors, targeting this pathway may be beneficial on a clinical basis. Our cluster analysis suggests that patient selection according to molecular tumor characteristics and associated clinical features may be feasible and lead to individualized targeted therapy of VS patients. From a clinical perspective, recurrent tumors might be targeted using antiangiogenic active compounds. Moreover, if VEGF-mediated VS protection through reduction of radiation sensitivity were proved, then a combination of radiation therapy and anti-VEGF treatment (especially in VS patients with high intratumoral VEGF levels) might improve treatment outcome.

Koutsimpelas et al.
Acknowledgments

We thank Karin Backes for her technical expertise.

This work was funded by a grant provided by the Head and Neck Tumor Research Foundation, Wiesbaden, Germany. The foundation is a nonprofit organization. The funders played no role in the experiment design, execution, analysis or preparation of the paper.

Disclosure Statement

The authors have no conflicts of interest to declare.

References


